You are here: Industry Insights > Enbrel

News List

US Supreme Court Denies Sandoz Petition to Review Biosimilar Erelzi® Case americanpharmaceuticalreview
May 19, 2021
Sandoz has announced that the US Supreme Court has denied its petition to review the Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi® (etanercept-szzs) for reference medicine Enbrel®* (etanercept).
Federal Circuit Rules Upholds Lower Court Ruling in Biosimilar Erelzi Case americanpharmaceuticalreview
July 13, 2020
Sandoz, a Novartis division, announced the US Court of Appeals for the Federal District has ruled against Sandoz in patent litigation concerning the Sandoz biosimilar Erelzi® (etanercept-szzs) for reference medicine Enbrel® (etanercept).
Lupin and Mylan receive European Marketing Authorization for Nepexto, Biosimilar Etanercept expresspharma
June 05, 2020
A a phase 3 clinical study in patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to Enbrel in terms of efficacy, safety and immunogenicity.
Amgen wins court patent ruling over Sandoz biosimilar europeanpharmaceuticalreview
August 14, 2019
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
With Enbrel patent victory, Amgen scores major win against biosims—and Sandoz takes a big loss fiercepharma
August 13, 2019
Enbrel, its top-selling product, has steered clear of a major stumbling block, thanks to a victory in patent court that kicks potential biosimilars years down the road.
US court rules in favour of Amgen in Enbrel patent case pharmaceutical-technology
August 13, 2019
The US District Court for the District of New Jersey has upheld two of Amgen’s patents that claim its rheumatoid arthritis drug Enbrel (etanercept) and methods for making the medicine.
Enbrel and Its Patent Layout: The Period of Market Exclusivity until 2029! PharmaSources/zhixing
July 30, 2019
Patents are fortresses of new drugs. The patent layout of Enbrel is quite impressive: the span from the first application in 1995 to the patent expiration in 2029 reaches 34 years.
FDA Approves Eticovo drugs
May 06, 2019
FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel.
What do kids think of their parents' RA? Amgen's new Enbrel push offers a few ideas fiercepharma
August 10, 2017
Amgen has launched a new DTC campaign for arthritis drug Enbrel featuring children who have parents with the disease.
Novartis Says Court Battle Will Delay Its Enbrel Copy Until 2018 at Least firstwordpharma
January 26, 2017
Novartis said that a legal battle will delay the launch of Erelzi, a biosimilar of Amgen's Enbrel, until at least next year, as reported The New York Times Wednesday.